NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Tuesday that revenues for its fiscal second quarter dropped 11 percent year over year.

Total revenues for the three months ended Jan. 31 fell to $22.2 million from $25.0 million a year ago. By segment, clinical laboratory services shrank 6 percent to $13.3 million from $14.1 million, while product revenues slid 17 percent to $7.9 million from $9.5 million, and royalty and license fee revenues were down 23 percent to $1.0 million from $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.